Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
361-380 of 1,307 trials

Hypophosphatasia: ALXN1850 Treatment Study

We are studying a new treatment called ALXN1850 for adolescents and adults with hypophosphatasia who haven't been treated before. The goal is to see if it improves their daily functioning and quality of life compared to a placebo.

Hypophosphatasia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteEndocrinologyHematology

Hypophosphatasia in Children: ALXN1850 Study

We are studying a new treatment, ALXN1850, for children with hypophosphatasia who haven't been treated before. The goal is to see if it improves bone health and quality of life compared to a placebo.

Hypophosphatasia3-6 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteOrthopedics and TraumatologyPediatrics

Postoperative Pain Relief: Ibuprofen and Tramadol Combination

We are studying a new combination treatment for patients with severe pain after surgery to see if it provides better pain relief than tramadol alone and a placebo. This trial aims to assess both effectiveness and safety.

Acute Pain6-12 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesInternal MedicineOrthopedics and TraumatologyOtolaryngology

Axial Spondyloarthritis: Imaging with Technetium-labeled Certolizumab Pegol

We are studying whether a new imaging method can improve treatment decisions for people with axial spondyloarthritis. This may help doctors better assess disease activity and predict treatment responses.

Axial Spondyloarthritis>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesInternal MedicineRheumatology

Graft-versus-Host Disease: MC0518 Treatment Study

We are testing a new treatment, MC0518, for adults and adolescents with steroid-refractory acute graft-versus-host disease after stem cell transplantation. The study aims to see if it works better than the best available therapy and how it affects patients' quality of life.

Steroid Refractory Acute Graft Versus Host DiseaseConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Lung Cancer Treatment: Telisotuzumab Vedotin vs. Docetaxel

We are studying a new intravenous treatment for adults with previously treated non-squamous non-small cell lung cancer. The trial aims to see if it improves survival and quality of life compared to standard therapy.

Non-Squamous Non-Small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Hereditary Angioedema: PHA-022121 Treatment Study

We are testing the safety of a new oral medication for treating acute angioedema attacks in patients with hereditary angioedema. The study will also evaluate how well it relieves symptoms during these attacks.

Hereditary AngioedemaEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine

Lung Cancer Treatment: Livmoniplimab and Budigalimab

We are studying a new combination of drugs for adults with untreated metastatic non-squamous non-small cell lung cancer. The goal is to see if this combination works better than a standard treatment with pembrolizumab and chemotherapy.

Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Diabetic Retinopathy: COLIRIOBCN070660 Eye Drops

We are studying a new eye drop treatment for people with moderately severe to severe diabetic retinopathy. The goal is to see if it can reduce eye damage and improve vision.

Diabetic Retinopathy1-2 yearsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesEndocrinologyOphthalmology

Cardiovascular Disease: New Care Strategies for Type 1 Diabetes

We are testing a new care approach to reduce cardiovascular disease risk in people with type 1 diabetes. This study also evaluates the safety of a medication called finerenone in this high-risk group.

Type 1 Diabetes>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteCardiologyEndocrinologyInternal Medicine

Nonsegmental Vitiligo: Ritlecitinib Study

We are investigating the safety and effectiveness of ritlecitinib in adults and adolescents with nonsegmental vitiligo. This study looks at how well the medication works over time for those who have already been treated.

Non-Segmental Vitiligo1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Baricitinib for Uveitis in Children with Juvenile Idiopathic Arthritis

We are studying whether the oral medication baricitinib is safe and effective for children aged 2 to under 18 with active uveitis linked to juvenile idiopathic arthritis. This research aims to improve treatment options for these young patients.

UveitisConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOphthalmologyRheumatology

Hidradenitis Suppurativa: New Antibiotic Treatment Study

We are evaluating a new antibiotic regimen for people with Hurley stage 2 Hidradenitis Suppurativa to see if it works better than standard treatment. The study will also look at pain relief and quality of life improvements.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesDermatologyInfectious Diseases

Epcoritamab for Relapsed Primary CNS Lymphoma

We are studying the effects of epcoritamab in patients with relapsed primary diffuse large B-cell lymphoma of the CNS who have been treated with lenalidomide and rituximab. The trial aims to evaluate its effectiveness, safety, and impact on quality of life.

Relapsed and Refractory Primary Diffuse Large B-Cell Lymphoma of the CNS>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyNeurologyOncology

Asthma Management: BIRDIE Trial

We are exploring if we can safely extend the dosing schedule of two asthma medications for patients with severe eosinophilic and T2-high asthma. This study looks at whether this approach maintains asthma control.

Severe AsthmaConfirmation phase (III)No PlaceboStandard MedicinesAllergologyPulmonology

Chronic Pain Prevention: Duloxetine for Hernia Surgery

We are studying whether duloxetine can help prevent chronic pain in patients at high risk after inguinal hernia repair. We will also compare its safety to a placebo.

Chronic Pain After Surgery3-6 monthsConfirmation phase (III)Investigational MedicinesPartially RemoteInternal MedicineNeurologyOrthopedics and Traumatology

Colchicine for Heart and Kidney Health in Chronic Kidney Disease

We are studying whether low-dose colchicine can help prevent heart problems and slow kidney disease in people with moderate chronic kidney disease. This trial will also look at the safety of the treatment and its effects on inflammation.

Chronic Kidney Disease>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCardiologyNephrology

Breast Cancer Treatment: OP-1250 vs Standard Care

We are studying a new medication, OP-1250, for people with advanced or metastatic ER+, HER2- breast cancer. The goal is to see if it is safer and more effective than current standard treatments.

Estrogen Receptor Positive Breast CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Rosacea Treatment: Ivermectin Cream vs. Soolantra

We are studying a new ivermectin cream for people with papulopustular rosacea to see if it works better than Soolantra and a cream without active ingredients. The trial will assess how well it reduces bumps and redness on the face.

Papulopustular RosaceaConfirmation phase (III)6-10 visitsInvestigational MedicinesDermatology

Acute Myeloid Leukemia: Personalized Treatment Based on FLT3 Mutation

We are studying a new treatment strategy for patients with FLT3-positive AML, using a biomarker to tailor therapy. The goal is to see if this approach improves survival compared to standard treatments.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology